Biotech Founders
A verified directory of 264 biotech founders — sorted by modality, how far the lead programme has travelled, and where the company spun out of.
Last verified
- 264
- Biotech founders
- 231
- Companies
- 41%
- On licensed university IP
- 23%
- Clinical-stage asset
Verified in the last 30 days
Scientific co-founders share one
Spun out with an institutional licence
Phase 1 or beyond, not preclinical
Free preview
6 of 264 profiles
Names, roles, companies and live signals are public. Verified emails and LinkedIn URLs stay masked until you sign in.
- 01
Sunniva Adekoya-Thorncastle
Co-founder & CEO · Alderhaugh Therapeutics
Kendall Square, Cambridge
Dosed the first Phase 1 patient in June after a two-year IND-enabling package.
- Small molecule
- Phase 1
- University spin-out
- First dosing
- s•••••@alderhaughtx.com Locked
- 02
Marcelino Oyelaran-Hesketh
Founder & Chief Scientific Officer · Pentreath Biosciences
Mission Bay, San Francisco
Platform company with no owned asset; signed a third pharma discovery deal in July.
- Platform and tools
- Discovery
- Independently founded
- Partnering
- m•••••@pentreathbio.com Locked
- linkedin.com/in/•••••• Locked
- 03
Ottilie Nwankwo-Braithwaite
Co-founder & CEO · Marrowfield Cell Therapy
Seaport, Boston
Building an in-house manufacturing suite after a CDMO slot slipped by seven months.
- Cell and gene
- Preclinical
- University spin-out
- Manufacturing build
- o•••••@marrowfieldct.com Locked
- linkedin.com/in/•••••• Locked
- 04
Anwar Skjoldborg-Fitzhugh
Founder · Quarrenden Bio
Torrey Pines, San Diego
Left a large pharma antibody group in January with three colleagues and a licensed programme.
- Biologics
- Discovery
- Pharma spin-out
- Newly formed
- a•••••@quarrendenbio.com Locked
- linkedin.com/in/•••••• Locked
- 05
Ludmila Tetteh-Vandenbroucke
Co-founder & CEO · Silverthorn RNA
Research Triangle Park, NC
Company built inside a fund; board is still running the search for a permanent CEO.
- RNA
- IND filed
- Venture-created
- Leadership in flux
- l•••••@silverthornrna.com Locked
- linkedin.com/in/•••••• Locked
- 06
Barnabas Ekwueme-Sandhurst
Co-founder & President · Hollowmere Oncology
University City, Philadelphia
Phase 2 readout expected in Q1; opened a clinical operations hire and a CMC lead.
- Small molecule
- Phase 2 or later
- Independently founded
- Readout ahead
- b•••••@hollowmereonc.com Locked
- linkedin.com/in/•••••• Locked
Unlock the full Biotech Founders list
The other 258 profiles are in Articuler. A free account runs 3 directory matches a day — every match returns full profiles with verified emails and LinkedIn URLs. Upgrade for unlimited matches, filtering and export.
Sign in to unlock the full listFree account · No credit card · Takes about 30 seconds
Opens Articuler search for “Biotech Founders”
Frequently asked questions
- Why is programme stage more useful here than funding stage?
- Because in biotech the two come apart. A company can raise a large Series A on a discovery-stage platform and a smaller one with an asset already in Phase 1, and the money says nothing about what the team is doing this quarter. 88 of these founders are in discovery and 61 have something in the clinic — the second group is running trial sites and talking to regulators, the first is still choosing targets.
- What changes if the company is a university spin-out?
- The licence terms do, and they are permanent. 107 founders here operate under an institutional licence with milestones, sublicensing conditions and often a royalty stack that shapes every partnering conversation for the life of the company. It also means a technology transfer office had a say in the cap table before any investor did.
- Are platform companies with no asset really biotech founders?
- 60 of them are here, and they are worth separating rather than excluding. A platform without an owned programme monetises through partnerships and service revenue, so its buying behaviour resembles a tools company far more than a therapeutics company. If you sell into R&D, that group is the one with a budget today.
- Which modality is hardest to reach cold?
- Cell and gene, generally. Those 46 founders spend a disproportionate share of their attention on manufacturing and CMC constraints that dominate the company's timeline, and outreach that does not acknowledge that reads as unfamiliar with the field. Small molecule founders, by contrast, are the most likely to have bandwidth for a first conversation.
- Do venture-created companies behave differently?
- 44 were founded inside a fund rather than by an independent team, and the practical difference is who decides. The founding investor typically holds board control from day one and often supplies the CFO and the search for a permanent CEO, so the person with the title may not be the person with the mandate. Worth knowing before investing months in one relationship.
- How do you verify a programme stage claim?
- Against registered trial records, published IND activity and company disclosures rather than pitch decks, refreshed on a rolling 30-day cycle with the last pass on 15 August 2026. Stage inflation is common in this sector — describing an IND-enabling study as clinical is an easy sentence to write — so anything that cannot be corroborated stays in the lower bucket.